Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (10077)	5/19/1999 1:16:00 AM
From: aknahow	Respond to of 17367

Bob, I don't want to tangle with Bluegreen or Cacaito, but I thought that at times a child with meningococcemia that had been treated with antibiotics would afterwards show no sign of n.m. in lab test, because the antibiotic treatment had killed it off. In fact at one point when the results of the P II trial were discussed the fact that 85% were lab confirmed cases was considered high since it is not uncommon for the bacteria to be eliminated by the antibiotic.

To: Robert K. who wrote (10077)	5/19/1999 9:34:00 AM
From: aknahow	Respond to of 17367

Who says you can't say anything to shareholders first! ''One of the challenges in treating multiple myeloma is that the patients' tolerance for radiation therapy decreases as the dose of chemotherapy increases'', said Paul G. Abrams, M.D., J.D., NeoRx's CEO. ''Skeletal Targeted Radiotherapy (''STR'') is designed to deposit radiation in the bone where the tumor cells have lodged, while avoiding radiation to non-target organs. Although patient numbers are too small to predict a response rate, preliminary Phase I data indicate that adding the therapeutic radiation of STR to chemotherapy has produced complete tumor responses in a sizable fraction of patients without increasing toxicity.'' These data will be formally presented at an international scientific meeting in July. Stock was up 37%. Note shareholders told first with full information to be presented at scientifc meeting in July.